[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053310":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":20,"locations":25,"responsibleParty":49,"collaborators":53,"id":57,"slug":20,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":20,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":28,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: High-Dose tDCS Intervention","EXPERIMENTAL","Participants in this single-arm, open-label pilot study will receive high-dose transcranial direct current stimulation (tDCS) for major depressive disorder. Each participant undergoes twice-daily 20-minute sessions at 6 mA for five consecutive weekdays (total of 10 sessions).\n\nThe first three participants complete an in-lab dose-escalation safety run-in (2 mA → 4 mA → 6 mA on Day 1) with a Day 2 skin integrity check before continuing at 6 mA twice daily for the remaining days.\n\nAll participants complete baseline, post-intervention, and 4-week follow-up assessments of depressive symptoms, cognition, and tolerability.",[13],"Device: Transcranial Direct Current Stimulation (tDCS)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Transcranial Direct Current Stimulation (tDCS)","Participants receive transcranial direct current stimulation (tDCS) using a high-dose (6 mA) protocol delivered twice daily for five consecutive weekdays (10 sessions total). The first three participants complete a Day 1 in-lab dose-escalation (2 mA → 4 mA → 6 mA) with a Day 2 skin integrity check before continuing at 6 mA. All sessions last 20 minutes and are followed by adverse-event monitoring.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Clayton Olash, MD","STUDY_DIRECTOR",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"MUSC Brain Stimulation Lab","RECRUITING","Charleston","South Carolina","29407","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-79.93275,32.77632,{"lat":38,"lon":37},[41,45],{"name":23,"role":42,"phone":43,"phoneExt":20,"email":44},"CONTACT","5023778275","olash@musc.edu",{"name":46,"role":42,"phone":47,"phoneExt":20,"email":48},"Elisabeth Collins, BS","8437928292","brainstimlab@musc.edu",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Mark George","Distinguished University Professor of Psychiatry, Radiology and Neuroscience",[54],{"name":55,"class":56},"National Institute on Drug Abuse (NIDA)","NIH","100053310",false,"NCT07226011","Accelerated High-Dose tDCS for Depression","Accelerated High-Dose tDCS for Depression: An Open-Label Outpatient Pilot Study","Inclusion Criteria:\n\n* Ages 18-70.\n* Current MDD diagnosis (MINI v7).\n* Baseline PHQ-9 \\> 9.\n* Capacity to consent\n* Fluent English.\n\nExclusion Criteria:\n\n* Bipolar or psychotic disorder\n* Primary anxiety disorders without concomitant major depression as defined above\n* Current significant suicidal ideation or behaviors require a higher level of care.\n* Use of neuromodulation therapies (e.g., ECT, TMS, VNS) within the past 6 months.\n* History of seizures, implanted cranial\u002F cardiac metal, or neurosurgery.\n* Use of medications that significantly reduce seizure threshold\n* Frequent\u002Fsevere HA\n* Personal history of head trauma, concussion, or TBI\n* Catatonic or otherwise unable to perform the consent process\n* Current alcohol or substance-use disorder (moderate-severe).\n* Any non-uniformities in the skin under the electrode site, including eczema, severe rashes, hyperhidrosis, communicable skin disorders, sensitive skin (ex. eczema, severe rashes), blisters, open wounds, burns including sunburns, cuts or irritation (e.g. due to shaving), or other skin defects or lesions, as determined by clinical personnel\n* Pregnancy (urine test required for women of childbearing potential).","ALL","18 Years","70 Years",{"count":67,"type":68},20,"ESTIMATED","INTERVENTIONAL",[71],"NA","In this study, investigators are testing whether a higher dose of a non-invasive brain stimulation technique, called transcranial direct current stimulation (tDCS), can be safely used in people with depression. Participants will come to the Brain Stimulation Lab and receive mild electrical stimulation through electrodes placed on their scalp.\n\nThe study begins with a safety run-in, where the first few participants will receive stimulation at gradually increasing levels (2, 4, and 6 milliamps) while being closely monitored. If no serious side effects are found, later participants will receive repeated 6 milliamp sessions for 5 days total. Investigators will check skin comfort, mood, and overall tolerability after each session.",[74,75],"Major Depression","Major Depression Disorders",[77,78,79,80,81,82],"Depression","Nervous System","tDCS","Interventional","Brain Stimulation","Transcranial Direct Stimulation","2026-07-10",{"date":85,"type":86},"2026-07-13","ACTUAL",{"date":88,"type":86},"2025-12-15",{"date":90,"type":68},"2026-10-01",{"name":5,"class":6},1]